IFNB1 and myeloid sarcoma: Despite the effectiveness of IFN-β in reducing the severity of symptoms in MS, not all patients respond favourably and in some cases patients cease treatment due to ineffectiveness or side effects, including PD-like symptoms (Manouchehrinia and Constantinescu, 2012).